Wedbush Securities’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Wedbush Securities’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,500	Closed	-$15K	–	903
2016 Q2	$15K	Hold	3,500	–	–	﹤0.01%	772
2016 Q1	$20K	Buy	3,500 +1,950	+126%	+$25.3K	﹤0.01%	729
2015 Q4	$27K	Buy	1,550 +300	+24%	+$7.15K	﹤0.01%	707
2015 Q3	$26K	Buy	+1,250	New	+$42.8K	0.01%	691

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wedbush Securities's OREX Position: Q3 2016 in Review

Wedbush Securities sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 3,500 shares — an estimated $15K sold.

Wedbush Securities first reported a position in OREX in Q3 2015 and held it in 4 quarters. The position peaked at $27K in Q4 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

Wedbush Securities reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Wedbush Securities sold 3,500 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $15K.
Wedbush Securities first reported a position in Orexigen Therapeutics, Inc. in Q3 2015 and held it in 4 quarters.
Wedbush Securities's Orexigen Therapeutics, Inc. position peaked at $27K in Q4 2015.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Wedbush Securities's 13F filing for Q3 2016, filed 4 Nov 2016.